REG - Futura Medical PLC - Formal Grant of US Patent

Futura MedicalAnnouncement

18/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260318:nRSR0454Xa&default-theme=true

RNS Number : 0454X  Futura Medical PLC  18 March 2026

18 March 2026

Futura Medical plc

("Futura", "the Group" or the "Company")

Formal Grant of US Patent

 

Further to its announcement on 5 February 2026, Futura Medical (AIM: FUM), the
consumer healthcare Group behind Eroxon® and that specialises in the
development and global commercialisation of innovative and clinically proven
sexual health products, is pleased to announce that the US Patent Office has
formally granted its US continuation patent No. 12,576,152 which will provide
additional protection for Eroxon® (including formulation derivatives such as
the Eroxon® Intense formulation) and women's product WSD4000 (currently in
development) until 2040 in the US.

 

Under the terms of its existing licence agreement with Haleon, the granting of
this patent is expected to trigger a US patent milestone payment of US$2.5
million.

 

Contacts:

 Futura Medical plc                          Alex Duggan                                             investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                             Chief Executive Officer

                                                       +44 (0)1483 685 670
                                             Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  Guy McDougall, Andrew Thacker                           +44 (0)20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters        +44 (0)20 3405 0205

                                                                                                     futura@almastrategic.com

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and development products WSD4000
and Eroxon(®) Intense. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. Erectile Dysfunction
("ED") impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. Around 60% of women experience at least one
symptom of sexual dysfunction, and only one in four women seek professional
help, and remain chronically underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection in ten minutes, addresses significant unmet needs in the ED market.
Eroxon(®) has been nominated for a number of healthcare industry awards and
has won two to-date. Multiple distribution partnerships are in place for
Eroxon, across major consumer markets.

 

The WSD4000 is a prototype product designed for the symptoms of impaired
sexual response and function in women. There is currently no regulatory
approved OTC treatment available for impaired sexual response and function in
women. WSD4000 has the potential to be an effective, breakthrough treatment
for the common symptoms associated with impaired sexual response and function,
such as lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFAEFWEMSEED



            Copyright 2019 Regulatory News Service, all rights reserved